Wahiduzzaman Mohammed, Sharma Chandresh, Dey Bindu, Bhatla Neerja, Singh Neeta
Department of Biochemistry, All India Institute of Medical Sciences, Room No. 3027A, New Delhi, 110029, India,
Immunol Res. 2015 Jun;62(2):189-97. doi: 10.1007/s12026-015-8650-4.
Human papillomaviruses (HPVs) are prerequisite for the development of cervical cancer, with HPV16 and HPV18 being the most prevalent. Despite the fact that two prophylactic vaccines against HPVs are in the market, wide-scale application of the vaccine in developing countries is a major problem as far as cost of the vaccine and lack of therapeutic efficacy are concerned. Hence, the aim of our study was to develop HPV18 L1E7 chimeric virus-like particles (CVLPs) vaccine candidate possessing both, prophylactic and therapeutic potential against HPV18-associated cervical cancer. In this study, we have developed a potential candidate vaccine against HPV18 involving HPV18 L1E7 CVLPs, which was expressed in E. coli and assembled in vitro. These CVLPs were able to induce a neutralizing antibody response as well as a cell-mediated immune response in mice.
人乳头瘤病毒（HPV）是宫颈癌发生的必要条件，其中HPV16和HPV18最为常见。尽管市场上有两种针对HPV的预防性疫苗，但就疫苗成本和缺乏治疗效果而言，在发展中国家广泛应用该疫苗是一个主要问题。因此，我们研究的目的是开发一种具有预防和治疗HPV18相关宫颈癌潜力的HPV18 L1E7嵌合病毒样颗粒（CVLP）候选疫苗。在本研究中，我们开发了一种针对HPV18的潜在候选疫苗，该疫苗涉及在大肠杆菌中表达并在体外组装的HPV18 L1E7 CVLP。这些CVLP能够在小鼠体内诱导中和抗体反应以及细胞介导的免疫反应。
